Form D · Pharmaceuticals
Kairos Pharma, LTD.
Los Angeles, CA · CIK 0001962011
Offering snapshot reported Jan 28, 2025 · SEC filing
- Reported sold
- $3.5M Offering amount: $8.75M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 16, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 28, 2025 | Initial | $3,497,500 | No comparison | 1 | SEC filing |
| Apr 27, 2023 | Initial | $675,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $280K
- Finders' fees
- $0
- Form D file number
- 021-536526
Offering amount includes pre-funded warrants plus exercise price of warrants to purchase common stock. Total Remaining to be Sold consists of the aggregate exercise price of common stock underlying warrants.
Issuer paid placement agents cash compensation equal to 8% of the gross proceeds from the offering and issued warrants to purchase 175,000 shares of common stock.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Boustead Securities, LLC | 000141391 | D. Boral Capital LLC · CRD 000103972 |
Source: Form D, filed Jan 28, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Hyun W. Bae | Director |
| Neil Bhowmick | Executive |
| Hansoo Michael Keyoung | Director |
| Ramachandran Murali | Executive |
| Doug Samuelson | Executive |
| Rahul Singhvi | Director |
| John S. Yu | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2355 Westwood Blvd., #139
Los Angeles, CA, 90064
Los Angeles, CA, 90064